Clin2
NCT06335160Possibly a fitRecruiting

Mebendazole for mild to moderate ulcerative colitis

Ulcerative Colitis

Treatments studied

Part of Digestive system clinical trials.

This study tests adding a medicine called mebendazole (normally used for parasites) to standard mesalamine treatment for people with mild or moderate ulcerative colitis. The goal is to see if it helps control inflammation better than mesalamine alone.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
46 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have been diagnosed with mild or moderate ulcerative colitis.
  • You are already taking mesalamine (a medicine for colon inflammation).
  • You are not currently on steroids, immune-suppressing drugs, or other biologic treatments.
  • You do not have certain health issues like severe heart problems, diabetes, liver or kidney disease, or a history of seizures.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06067698Recruiting
Alpha lipoic acid for mild to moderate ulcerative colitis

This trial tests whether adding alpha lipoic acid (an antioxidant) to your usual mesalamine treatment helps control mild to moderate ulcerative colitis. It is for people newly diagnosed and not on other UC treatments.

Tanta
NCT06993974Recruiting· Phase 2
Nitazoxanide for mild to moderate ulcerative colitis

This trial tests if a medication called nitazoxanide can help people with mild to moderate ulcerative colitis (UC). It may be a treatment option for those not already on strong UC medications.

Alexandria
NCT06420375Recruiting· Phase 2
New treatment for active ulcerative colitis

This trial tests a new treatment for people with ulcerative colitis (UC) whose disease is active despite taking only mesalamine or sulfasalazine. It aims to find a therapy that can reduce inflammation and improve symptoms.

Chestnut Hill, Massachusetts
NCT06525974Not yet recruiting· Early Phase 1
Febuxostat for mild to moderate ulcerative colitis

This trial tests if adding febuxostat to your usual mesalamine treatment can help improve mild to moderate ulcerative colitis. It's for adults with confirmed UC who are not on steroids or other immune-suppressing drugs.

NCT07389824Recruiting
Acupuncture plus mesalazine for ulcerative colitis

This study tests whether adding acupuncture (using small intradermal needles) to the standard medication mesalazine improves outcomes for people with mild-to-moderate ulcerative colitis. Participants receive 12 acupuncture sessions and undergo two colonoscopies to assess the treatment's effect.

Wuhan, Hubei
NCT04908644Recruiting
Oral MS-20 for moderate to severe ulcerative colitis

This trial studies whether an oral treatment called MS-20 can improve ulcerative colitis (UC) in adults with moderate to severe disease. You may be asked to provide stool samples from home and avoid certain foods and medicines before screening and during the study.

Taipei

Hear when a new Ulcerative Colitis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.